What is The BioCollective?
The BioCollective® is a biotechnology firm dedicated to advancing microbiome research and the development of novel therapeutics. The company has developed proprietary tools, including its BioFlux technology, to enhance the accuracy, repeatability, and verifiability of microbiome research. Their innovative methods span sample collection, homogenization, processing, banking, and computational biology, with a particular focus on unlocking the value of human fecal samples to understand and address pressing health conditions. The BioCollective's work is crucial in understanding the multi-system impact of the microbiome on human health, positioning them as leaders in the field.
How much funding has The BioCollective raised?
The BioCollective has raised a total of $1.1M across 2 funding rounds:
Private Equity
$1M
Debt
$81K
Private Equity (2016): $1M, investors not publicly disclosed
Debt (2021): $81K led by PPP
Key Investors in The BioCollective
PPP
Public-Private Partnership
What's next for The BioCollective?
With its recent major enterprise-level funding, The BioCollective is poised for significant scaling and further innovation. The substantial expansion capital is expected to fuel advancements in their platform technologies and accelerate the development pipeline for microbiome-based therapeutics. This strategic investment will likely enable the company to broaden its research collaborations, enhance its computational biology capabilities, and potentially expand its market reach in the rapidly growing field of microbiome science. The company's focus on verifiable and repeatable research methods suggests a trajectory towards clinical validation and commercialization of its discoveries.
See full The BioCollective company page
